Date: 2017-01-09
Type of information: Construction of new premises
Compound: new manufacturing facility in Athlone
Company: Aerie Pharmaceuticals (USA - CA) IDA Ireland (Ireland)
Therapeutic area: Ophtalmological diseases
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On January 9, 2017, Aerie Pharmaceuticals has entered into a lease agreement with IDA Ireland to establish a new manufacturing plant in the recently constructed 2,650m2 IDA Advanced Technology Building in Athlone, Ireland. The project is supported by the Department of Jobs, Enterprise & Innovation through IDA Ireland. The Athlone facility will house Aerie’s first manufacturing plant, which is expected to produce commercial supplies for Aerie’s current product candidates, Rhopressa™ and Roclatan™. If approved, these products are expected to offer the first new mechanisms of action for treatment of patients with glaucoma in some 20 years. Estimated project-wide construction and equipment costs are expected to total approximately €25 million (excluding ongoing labor-related and lease expenses), and commercial product supply for Rhopressa™, if approved, is expected to be available by 2020. Aerie has commenced its design plan for the facility and expects to begin internal construction in early 2017. The company will initially create up to 50 new jobs in sterile manufacturing, quality, engineering and other support capabilities.
Financial terms:
Latest news:
